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ABSTRACT Microsomal postaglandin (PG) E synthase
(mPGES)-1 is an inducible enzyme that acts downstream of
cyclooxygenase (COX) and specifically catalyzes the conver-
sion of prostaglandin (PG)H2 to PGE2, most prominently in
inflammatory conditions. Specific inhibitors ofmPGES-1 are
not yet available, however, mice with genetic deletion of
mPGES-1 have been generated that have given insight into
the specific role of mPGES-1 in eicosanoid biosynthesis in
vivo and in peritoneal macrophages. We created mouse
embryo fibroblast (MEF) cell lines that would facilitate
investigation of the effect of mPGES-1 genetic deletion on
prostanoid biosynthesis in fibroblast lineage cells and its
subsequent effect on the expression of inducible NOS
(iNOS) and nitrite biosynthesis using cells derived from
mPGES-1 wild-type (WT), heterozygous (Het), and null
mice. The results show that genetic deletion of mPGES-1
results in a dramatic decrease in PGE2 production in Het
and null MEFs under basal conditions and after stimulation
with interleukin (IL)-1, suggesting thatmPGES-1 is critically
important for PGE2 production. Furthermore, we show that
mPGES-1 gene deletion results in diversion of prostanoid
production from PGE2 to 6-keto PGF1 (the stable meta-
bolic product of PGI2; prostacyclin) in a gene dose-depen-
dent manner in Het and null MEFs compared with their WT
counterparts, suggesting a shunting phenomenon within the
arachidonic acid (AA) metabolic pathway. In addition, we
show that mPGES-1 gene deletion and subsequent decrease
in PGE2 levels results in a differential induction profile of
iNOS and nitrite levels (the stable breakdown product of
nitric oxide (NO) in mPGES-1 WT MEFs compared with
null MEFs. These results provide important information
regarding the therapeutic potential for pharmacologic inhi-
bition of mPGES-1 in inflammatory conditions.—Kapoor,
M., Kojima, F., Qian, M., Yang, L., and Crofford, L. J.
Shunting of prostanoid biosynthesis in microsomal prosta-
glandin E synthase-1 null embryo fibroblasts: regulatory
effects on inducible nitric oxide synthase expression and
nitrite synthesis. FASEB J. 20, E1704–E1715 (2006)
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During an inflammatory insult, one of the essential
fatty acids released by cell membrane phospholipids is
AA, which is subsequently metabolized by a series of
enzymatic reactions to yield biologically active media-
tors. COX-1 and -2 convert AA into PGH2, which
is further metabolized by terminal PG synthases to
PGE2, 6-keto PGF1, PGD2, PGF2, and thromboxane
(TX) A2.
Among these prostanoids, PGE2 is a key mediator of
inflammation. Nonsteroidal antiinflammatory drugs
(NSAIDs), including COX-2-selective NSAIDs, mediate
their antiinflammatory effects by inhibiting the induc-
ible COX-2 enzyme and decreasing the production of
PGE2 at inflammatory sites (1–3). However, gastrointes-
tinal, renal, and the recently reported cardiovascular
side effects associated with the pharmacological inhibi-
tion of the COX enzymes (4–8) have led to renewed
attention to other potential targets for antiinflamma-
tory drugs. One of the most promising of these is the
inducible form of PGE synthase, which acts down-
stream of COX enzymes and specifically converts PGH2
to PGE2 after an inflammatory insult (9–12).
Three PGE synthases, including cytosolic PGE syn-
thase (cPGES), mPGES-1, and mPGES-2, have been
cloned and characterized (9, 11, 12). cPGES is localized
in the cytosolic region of a variety of cells and tissues
under basal conditions and is functionally coupled with
COX-1. cPGES is most likely to be involved in the
production of PGE2 for the maintenance of homeosta-
sis (11). mPGES-2 is also constitutively expressed in
wide variety of tissues and cell types and is synthesized
as a golgi membrane-associated protein (13). There
appears to be no differential coupling of mPGES-2 with
the COX enzymes. In contrast, mPGES-1 is an inducible
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enzyme that acts downstream of COX and specifically
catalyzes the conversion of PGH2 to PGE2 (9), most
prominently in inflammatory conditions (14, 15).
Based on observations in mice genetically deficient in
mPGES-1, this enzyme is a critically important mediator
of pain, angiogenesis, fever, bone metabolism, and
tumorgenesis (16–19).
We have previously shown that mPGES-1 expression
is increased in tissues and cells of various inflammatory
conditions, including rheumatoid arthritis (RA) and
osteoarthritis (OA) (14, 15, 20, 21). In addition, we
have also shown that mPGES-1 is essential for increased
PGE2 production. Furthermore, there are reports that
mPGES-1 null mice are resistant to chronic inflamma-
tion of joints in the models of collagen-induced arthri-
tis (CIA) and collagen antibody (Ab)-induced arthritis
(CAIA) (16, 17).
NSAIDs, including COX-2-selective inhibitors, are
used extensively to treat arthritis and other inflamma-
tory conditions. However, by inhibiting COX enzymes,
these drugs not only inhibit the production of the
major proinflammatory prostaglandin PGE2, but they
also block the synthesis of other prostanoids involved in
maintaining key physiological functions of a cell/tissue.
To overcome the limitations/side effects associated
with the inhibition of COX enzymes, mPGES-1 is an
attractive target to achieve more specific inhibition of
PGE2 production associated with inflammatory disor-
ders. However, it is critically important in preclinical
work to understand the potential consequences of
inhibiting this enzyme.
In the present study we demonstrate the conse-
quences of mPGES-1 genetic deletion on prostanoid
biosynthesis using mPGES-1 null mice-derived embryo
fibroblasts. The results show that genetic deletion of
mPGES-1 results in a dramatic decrease in PGE2 pro-
duction in mPGES-1 Het and null MEFs under basal
and proinflammatory cytokine stimulated conditions,
suggesting that mPGES-1 is critically important for
PGE2 production. This study further demonstrates
higher levels of 6-keto PGF1 in mPGES-1 Het and null
MEFs compared with their WT counterparts, suggest-
ing a shunting phenomenon within the AA metabolic
pathway associated with mPGES-1 deletion in a gene
dose-dependent manner. Furthermore, we show that
mPGES-1 gene deletion and resultant decrease in PGE2
production results in the elevation of iNOS expression
and nitrite levels in mPGES-1 null MEFs compared with
WT MEFs, suggesting that effects of mPGES-1 deletion
may not be restricted to differential production of
prostanoids within the AA metabolic pathway but can
affect the L-arginine metabolic pathway involving
iNOS.
MATERIALS AND METHODS
Animals
mPGES-1 null, Het, and littermate WT mice (DBA1 lac/J
background) were obtained from Pfizer Inc (Groton, PA,
USA) (17). COX-2 null and littermate WT mice (C57BL/6
background) were obtained from Robert Langenbach (Na-
tional Institute of Environmental Health Sciences, Research
Triangle Park, NC, USA) (22). Mice were housed in microiso-
lator cages in a pathogen-free barrier facility, and all experi-
ments were performed under the approved IACUC guide-
lines.
Materials
Rabbit anti-human mPGES-1 antiserum was gifted from Dr.
Per-Johan Jakobsson (Karolinska Institute, Stockholm, Swe-
den). Rabbit anti-mouse COX-2 polyclonal antibody (pAb),
rabbit anti-human mPGES-2 pAb, rabbit anti-human cPGES
pAb, rabbit anti-mouse PGI synthase (PGIS) pAb, rabbit
anti-mouse hematopoietic PGD synthase (H-PGDS) pAb, rab-
bit anti-human TX synthase (TXS) pAb, rabbit anti-mouse
COX-1 pAb, PGE2, NS-398 (N-[2-(cyclohexyloxy)-4-nitrophe-
nyl]-methanesulfonamide), ovine COX-2 standard protein
and ELISA kits for PGE2, 6-keto PGF1, PGD2 and TXB2 were
all purchased from Cayman Chemical Co. (Ann Arbor, MI,
USA). Rabbit anti-human eNOS pAb and rabbit anti-human
iNOS pAb were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Mouse anti-human beta-actin mono-
clonal antibody (mAb) and indomethacin were obtained
from Sigma Aldrich (St. Louis, MO, USA). Horseradish
peroxidase (HRP)-conjugated goat anti-rabbit IgG and HRP-
conjugated goat anti-mouse IgG were obtained from Jackson
ImmunoResearch (West Grove, PA, USA). Dulbecco’s modi-
fied Eagle medium (DMEM) and FBS were from Invitrogen
(Carlsbad, CA, USA). Recombinant mouse IL-1 was ob-
tained from R&D Systems (Minneapolis, MN, USA). TRIpure
was purchased from Roche Diagnostics (Indianapolis, IN,
USA). The polyvinylidene difluoride (PVDF) membrane and
enhanced chemiluminescence (ECL) reagent were pur-
chased from Amersham Pharmacia Biotech (Buckingham-
shire, UK).
Preparation and activation of mouse embryo fibroblasts
Embryos were harvested from mPGES-1 (DBA1 lac/J) or
COX-2 (C57 BL/6) pregnant Het females (E12.5) who had
been mated with Het males. Whole embryos were mixed and
placed into culture DMEM containing 10% FBS, 100 U/ml
penicillin, and 100 g/ml streptomycin at 37°C under an
atmosphere of 5% CO2. At confluence, the cells were de-
tached and passaged and the 3–4 passage cells were used in
the following experiments. MEFs were plated into the wells of
a 6-well plate at a density of 3  105 cells/well in DMEM
containing 10% FBS. Cells were starved for 72 h in DMEM
containing 1% FBS and then incubated with or without 1
ng/ml IL-1. Cell viability was determined by measuring
mitochondrial NADH-dependent dehydrogenase activity with
WST-1 assay (Dojindo Laboratories, Kumamoto, Japan).
Reverse transcription-polymerase chain reaction (RT-PCR)
RNA from the cells was extracted with TRIpure reagent
according to the manufacturer’s instructions. Reverse tran-
scription was performed according to the manufacturer’s
instructions using a SuperScript preamplification system (In-
vitrogen, Carlsbad, CA, USA) with 1 g of total RNA from the
cells as a template. Subsequent amplifications of the cDNA
fragments by PCR with HotStarTaq polymerase (Qiagen,
Valencia, CA, USA) were performed using 0.5 l of the
reverse-transcribed mixture as a template with specific oligo-
nucleotide primers and cycle number as follows: mouse
mPGES-1 (28 cycles), sense 5-CAC ACT GCT GGT CAT CAA
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GA-3, and antisense 5-ACA CCA AGT CCG CAA GTT C-3;
mouse COX-2 (25 cycles), sense 5-GGG CCC TTC CTC CAG
TAG CAG A-3, and antisense 5- CAG ACC AGG CAC CAG
ACC AA-3; mouse mPGES-2 (25 cycles), sense 5-GGT GGC
CCA GGA AGG AGA CAG C-3, and antisense 5-GCA GCC
GCG CCC ACA TAC TTG-3; mouse cPGES (30 cycles), sense
5-CCC GCC CAC CCG TTT GTC-3, and antisense 5-TCT
GGC ATC TTT TCA TCA TCA CTG-3; mouse PGIS (30
cycles), sense 5-TTC TGG CTC CTT CTT TTC CTC CTC-3,
and antisense 5-CTT CAG CCG TTT CCC ATC TTT GTA -3;
mouse H-PGDS (31 cycles), sense 5-ATG CCT AAC TAC AAA
CTG CTT-3, and antisense 5-CTA GAG TTT TGT CTG TGG
CCT-3; mouse TXS (30 cycles), sense 5-CCT CTG TGT GGG
TAC TAT CT-3, and antisense 5-TGG GAC CAT TAT GGA
TGG AA-3; mouse COX-1 (30 cycles), sense 5-CCC CAG
CCC TCC GAC CTA CAA-3 and antisense 5-CCC CGG AAG
CAA CCC AAA CAC-3; mouse GAPDH (20 cycles), sense
5-GGG GTG AGG CCG GTG CTG AGT AT-3, and antisense
5-TGG GGG TAG GAA CAC GGA AGG-3. After initial
denaturation at 95°C for 15 min, PCR involved amplification
cycles of 30 s at 95°C, 30 s at 56°C, and 45 s at 72°C, followed
by elongation for 5 min at 72°C. The amplified cDNA
fragments were resolved by electrophoresis on 2% (w/v)
agarose gel and were visualized under UV light using a
Bio-Rad Chemidoc Apparatus (Hercules, CA, USA) after
staining of the gel with ethidium bromide.
Western blotting
Cells were lysed in Tris-buffered saline (TBS) containing
0.1% sodium dodecyl sulfate (SDS), and the protein content
of the lysates was determined using bicinchoninic acid (BCA)
protein assay reagent (Pierce, Rockford, IL, USA) with BSA as
the standard. Cell lysates were adjusted to equal equivalents of
protein and then were applied to SDS-polyacrylamide gels
(10–20%) for electrophoresis. Next, the proteins were elec-
troblotted onto VDF membranes. After the membranes were
blocked in 10 mM TBS containing 0.1% Tween-20 (TBS-T)
and 5% skim milk, the membranes were probed for 1.5 h with
the respective antibodies (1:500 for mPGES-1, COX-2,
mPGES-2, cPGES, PGIS, H-PGDS, TXS, COX-1, eNOS, and
iNOS; 1:1000 for beta-actin) in TBS-T for 1.5 h. After washing
the membranes with TBS-T, the membranes were incubated
with HRP-conjugated anti-rabbit (for mPGES-1, COX-2,
mPGES-2, cPGES, PGIS, H-PGDS, TXS, COX-1, eNOS, and
iNOS) or HRP-conjugated anti-mouse (for beta-actin) IgG
(1:10,000 dilution in TBS-T containing 5% skim milk) for
overnight at 4°C. After further washing with TBS-T, protein
bands were visualized with an ECL Western blot analysis
system using a Bio-Rad Chemidoc Apparatus (Bio-Rad, Her-
cules, CA, USA).
Measurement of prostaglandins in culture medium
MEFs were incubated for 12 h in the presence or absence of
IL-1 (1 ng/ml). In experiments involving treatment with
indomethacin and NS-398, these compounds were added
72 h before IL-1 stimulation. The culture supernatant was
harvested and the concentrations of PGE2, 6-keto PGF1 (a
stable metabolite of PGI2), PGD2, and TXB2 (a stable metab-
olite of TXA2) were measured by ELISA. Assays were per-
formed according to the manufacturer’s recommendation.
Measurement of nitrite in culture medium
For measurement of nitrite in the cell supernatants, MEFs
were plated into the wells of a 6-well plate at a density of 3 
105 cells/well in phenol red free DMEM containing 10% FBS.
Cells were starved for 72 h in phenol red free DMEM
containing 1% FBS and then incubated for 12 h in the
presence or absence of IL-1 (1 ng/ml), with or without
indomethacin, NS-398, and PGE2. Nitrite concentrations
were measured in cell supernatants as an indicator of NO
production using a commercially available Griess reaction kit
(Cayman, Ann Arbor, MI, USA). Assay was performed accord-
ing to the manufacturer’s recommendation.
Statistical analysis
The data are expressed as mean  sem. Statistical analysis was
done using two-way ANOVA followed by Tukey test. P  0.05
was considered statistically significant.
RESULTS
Characterization of mPGES-1 WT, Het,
and null MEFs
We first characterized the genotype of mPGES-1 MEFs
using RT-PCR. Fig 1A shows the mRNA expressions for
mPGES-1 WT, Het, and null MEFs. In addition, we also
assessed the cell viability of mPGES-1 WT, Het, and null
MEFs with or without IL-1 stimulation using WST-1
cell viability assay. No change in the cell viability of
mPGES-1 WT, Het, and null MEFs was observed with or
without IL-1 stimulation (data not shown).
mRNA expression profile of prostanoid biosynthetic
enzymes in mPGES-1 WT and null MEFs
Incubation of mPGES-1 WT and null MEFs with IL-1
resulted in an up-regulation of mPGES-1 mRNA expres-
sion in mPGES-1 WT MEFs, with peak expression levels
observed at 3 h post IL-1 stimulation (Fig 1B), while
no band was detected in mPGES-1 null MEFs. COX-2
mRNA was coinduced with mPGES-1 mRNA in both
WT and null MEFs. However, the peak mRNA expres-
sion of COX-2 was observed at 1 h post IL-1 stimula-
tion in both WT and null MEFs, earlier to that of
mPGES-1 expression. In addition, we also observed that
IL-1 induced COX-2 mRNA expression in mPGES-1
null MEFs was higher compared with their WT coun-
terparts throughout the time course of 24 h.
We also determined whether mPGES-1 WT and null
MEFs expressed other prostanoid biosynthetic en-
zymes, including mPGES-2, cPGES, PGIS, H-PGDS,
TXS, and COX-1. Results showed that mPGES-2,
cPGES, PGIS, H-PGDS, TXS, and COX-1 were consti-
tutively expressed in WT and null MEFs as no signifi-
cant change in the mRNA expression levels of these
enzymes was observed throughout the time course of
24 h, post IL-1 stimulation. We did not observe
differences in expression of these enzymes comparing
mPGES-1 WT and null MEFs. (Fig 1B).
Protein expression profile of prostanoid biosynthetic
enzymes in mPGES-1 WT and null MEFs
Incubation of mPGES-1 WT and null MEFs with IL-1
resulted in an up-regulation of mPGES-1 protein ex-
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pression in mPGES-1 WT MEFs, with peak expression
levels observed at 48 h post IL-1 stimulation (Fig. 2).
COX-2 protein expression was coinduced with
mPGES-1 in both WT and null MEFs. However, the
peak protein expression of COX-2 was observed at 12 h
post IL-1 stimulation in both WT and null MEFs,
earlier than that observed for mPGES-1 protein expres-
sion. The protein expression profile of COX-2 and
mPGES-1 correlated to that observed at mRNA level.
However, we observed that IL-1 induced COX-2 pro-
tein expression in mPGES-1 WT MEFs was higher
compared with their null counterparts throughout the
time course of 48 h, opposite to what we observed for
COX-2 mRNA expression (Fig 1B).
The protein expression profile of other prostanoid
biosynthetic enzymes including mPGES-2, cPGES,
PGIS, H-PGDS, TXS, and COX-1 mirrored that of
mRNA levels. All enzymes were constitutively expressed
in WT and null MEFs, as no significant change in the
protein expression levels of these enzymes was observed
throughout the time course of 48 h, post IL-1 stimu-
lation (Fig. 2). No differences in protein expression of
these enzymes were observed in mPGES-1 WT MEFs
compared to null MEFs.
Differential pattern of endogenous prostanoid
production in mPGES-1 WT, Het, and null MEFs
Higher levels of endogenous PGE2 were observed in
mPGES-1 WT MEFs compared with significantly lower
(P0.05) baseline levels observed in mPGES-1 null
counterparts under unstimulated basal condition (Fig.
3A). On stimulation with IL-1, a significant increase
(P0.01) in the levels of PGE2 was observed in the
mPGES-1 WT MEFs, at 6, 12, and 24 h, peaking at 12 h
post IL-1 stimulation and correlating with the peak
expression profile of COX-2 protein as shown in Fig. 2.
However, IL-1 stimulation did not show any significant
change in the PGE2 levels in the mPGES-1 null MEFs
and the levels were significantly lower (P0.05 at 1 h;
P0.01 at 3, 6, 12, 24 h) compared with their IL-1
stimulated WT counterparts even though COX-2 pro-
tein was expressed. These results clearly suggest that
Figure 1. Effect of IL-1 on mRNA expression of COX and terminal PG synthase in mPGES-1 WT and null MEFs. A) Genotype
of mPGES-1 WT, Het, and null mice. mRNA levels of mPGES-1 (28 cycles) and GAPDH (20 cycles) from mPGES-1 WT, Het, and
null MEFs were determined by RT-PCR. B) mPGES-1 WT and null MEFs were harvested at 0, 1, 3, 6, 12, and 24 h post IL-1
stimulation, and mRNA expressions of mPGES-1 (28 cycles), COX-2 (25 cycles), mPGES-2 (25 cycles), cPGES (30 cycles), PGIS
(30 cycles), H-PGDS (31 cycles), TXS (30 cycles), COX-1 (30 cycles), and GAPDH (20 cycles) were detected by RT-PCR.
Representative data from three separate embryo lines are shown.
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mPGES-1 is vital for PGE2 production under basal
conditions but almost essential in conjunction with
COX-2 for PGE2 production during inflammatory con-
ditions.
We further determined the levels of endogenous
6-keto PGF1 in mPGES-1 WT and null MEFs. The
MEFs synthesize high levels of 6-keto PGF1, with 5-fold
higher 6-keto PGF1 levels compared to that of PGE2.
The levels of 6-keto PGF1 in mPGES-1 WT and null
MEFs showed a significant difference under normal
basal conditions with significantly higher levels
(P0.05) of 6-keto PGF1 observed in mPGES-1 null
MEFs. Stimulation with IL-1 resulted in a significant
increase (P0.01) in the levels of 6-keto PGF1 in
mPGES-1 null MEFs, at 1, 3, 6, 12, and 24 h, peaking at
6–12 h post IL-1 stimulation. In contrast, stimulation
with IL-1 exhibited almost negligible up-regulation in
the levels of 6-keto PGF1 in mPGES-1 WT MEFs
compared with mPGES-1 null MEFs (Fig 3A). Levels of
PGD2 and TXB2 were also assessed; however, no signif-
icant change in the levels of PGD2 and TXB2 was
observed with and without IL-1 stimulation at any time
points in mPGES-1 WT MEFs and null MEFs (Fig 3A).
These results suggest that genetic deletion of
mPGES-1 shifts prostanoid production profile from
PGE2 to 6-keto PGF1 in cells where these are the
dominant PG products. To further confirm the differ-
ential shift in the prostanoid production, we deter-
mined the levels of PGE2 and 6-keto PGF1 in IL-1
stimulated and unstimulated mPGES-1 WT, Het, and
null MEFs. The results clearly suggest that deletion of
mPGES-1 gene directly results in the up-regulation of
6-keto PGF1 levels in mPGES-1 Het and null MEFs vs.
PGE2 production in mPGES-1 WT MEFs in a gene
dose-dependent manner (Fig 3B).
Effect of nonselective and selective COX-2 inhibition
on the levels of PGE2 and 6-keto PGF1 in mPGES-1
WT and null MEFs
To evaluate the contribution of COX-2 (upstream
enzyme for mPGES-1) toward the production of PGE2
and 6-keto PGF1, we determined the effects of the
nonselective COX inhibitor, indomethacin, and the
selective COX-2 inhibitor, NS-398, on the prostanoid
production profile. Treatment with indomethacin and
NS-398 significantly inhibited the production of both
PGE2 and 6-keto PGF1 in IL-1 stimulated and un-
stimulated WT and null MEFs (Fig. 4). Since indometh-
acin and NS-398 showed similar extent of prostanoid
inhibition, these results suggest that COX-2, and not
COX-1, is the main upstream enzyme responsible for
the production of PGE2 and 6-keto PGF1 in MEFs.
Figure 2. Effect of IL-1 on protein expression of COX and terminal PG synthase in mPGES-1 WT and null MEFs. mPGES-1 WT
and null MEFs were harvested at 0, 6, 12, 24, and 48 h post IL-1 stimulation and protein expressions of mPGES-1, COX-2,
mPGES-2, cPGES, PGIS, H-PGDS, TXS, COX-1, and -actin were determined by Western blotting. Representative data from
three separate embryo lines are shown.
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Effect of genetic deletion of COX-2 on the levels of
PGE2 and 6-keto PGF1 in COX-2 WT, Het, and null
MEFs
To further evaluate the contribution of COX-2 toward the
production of PGE2 and 6-keto PGF1, we assessed the
levels of these prostanoids in the MEFs isolated from mice
with a genetically deleted COX-2 gene (Fig 5A). The levels
of PGE2 and 6-keto PGF1 observed in the COX-2 WT
MEFs (isolated from mouse on C57BL/6 background)
were almost similar to what we observed for mPGES-1 WT
MEFs (isolated from mice on DBA1/lacJ background),
including higher absolute levels of 6-keto PGF1 than
PGE2 (Fig 5B). Thus, using MEFs from two different
background strains did not result in a dramatic change in
the levels of these prostanoids.
Stimulation with IL-1 resulted in a significant in-
crease in the levels of PGE2 in the COX-2 WT MEFs
Figure 3. Differential production pattern of PGE2 vs. 6-keto PGF1 in mPGES-1 null MEFs. A) Levels of PGE2, 6-keto PGF1,
PGD2, and TXB2 in supernatants of mPGES-1 WT and null MEFs were detected by ELISA at 0, 6, 12, and 24 h post IL-1
stimulation. Data are expressed as the mean  sem for 3–4 embryo lines. *WT control vs. WT IL-1; #null control vs. null IL-1;
$WT control vs. null control; £WT IL-1 vs. null IL-1. Single and double characters indicate significance at P  0.05 and P 
0.01, respectively. B) Levels of PGE2 and 6-keto PGF1 in supernatants of mPGES-1 WT, Het, and null MEFs were detected by
ELISA at 12 h post IL-1 stimulation. Data are expressed as the mean  sem for three embryo lines. *, **Indicate statistical
significance at P  0.05 and P  0.01, respectively.
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(Fig 5B). However, IL-1 stimulation had no effect on
the levels of PGE2 in COX-2 null MEFs, which re-
mained unaltered compared to the unstimulated
COX-2 null MEFs. Similarly, IL-1 stimulation signifi-
cantly increased the levels of 6-keto PGF1 in COX-2
WT MEFs. However, the levels of 6-keto PGF1 were
almost undetectable in IL-1 stimulated and unstimu-
lated COX-2 null MEFs (Fig 5B).
Effect of mPGES-1 genetic deletion and subsequent
decrease in PGE2 production on iNOS and eNOS
expression
eNOS and iNOS are the key NOS enzymes known to be
involved in various physiological and pathophysiologi-
cal processes. Recent studies have suggested crosstalk
between NOS, PGE2 and PG biosynthetic enzymes in
inflammatory conditions (23). Therefore, we investi-
gated the effect of mPGES-1 genetic deletion on the
expression level of eNOS and iNOS enzymes.
eNOS was expressed constitutively in mPGES-1
MEFs, as no change in the eNOS expression was
observed with mPGES-1 gene deletion or by IL-1
stimulation. iNOS protein expression was undetectable
in unstimulated mPGES-1 WT and null MEFs (Fig. 6).
However, on stimulation with IL-1 there was an induc-
tion of iNOS protein (12 h post IL-1 stimulation).
iNOS protein expression levels were higher in the
mPGES-1 null MEFs compared to their WT counter-
parts, indicating that mPGES-1 may in part be respon-
sible for the differential expression of iNOS.
We further investigated the contribution of COX-2
(upstream enzyme to mPGES-1) toward the differential
regulation of iNOS expression observed in mPGES-1
WT and null MEFs using nonselective COX and selec-
tive COX-2 inhibitors. Results showed that incubation
of IL-1-stimulated mPGES-1 MEFs with indomethacin
and NS-398 increased the expression levels of iNOS in
only mPGES-1 WT MEFs, elevating the levels similar to
that observed in null MEFs (Fig. 6). These results
demonstrate that in the absence of mPGES-1 deletion
(as observed in mPGES-1 WT MEFs), inhibition of
COX-2 contributes toward the up-regulation of iNOS
expression. Similarly, in the presence of mPGES-1
genetic deletion (mPGES-1 null MEFs), nonselective
COX and selective COX-2 inhibitors exhibit no effect
on iNOS expression. These results indicate that
mPGES-1 and COX-2-derived PGE2 contribute to the
regulation of iNOS in MEFs.
To further evaluate the contribution of PGE2 toward
regulation of iNOS, we determined the effects of exog-
enous PGE2 on iNOS expression. PGE2 treatment sub-
stantially decreased the level of iNOS expression in
mPGES-1 null MEFs, bringing down the levels similar to
WT MEFs, while no change in the levels of iNOS
expression was observed in mPGES-1 WT MEFs. Thus,
these results clearly suggest that mPGES-1 and COX-2-
derived PGE2 negatively regulate iNOS expression in
MEFs.
Differential level of nitrite biosynthesis in mPGES-1
WT and null MEFs
NO generated by metabolism of L-arginine by NOS
enzyme is highly unstable and is rapidly converted into
Figure 4. Effect of indomethacin and NS-398
on PGE2 and 6-keto PGF1 production in
mPGES-1 WT and null MEFs. mPGES-1 WT
and null MEFs were incubated with or with-
out IL-1 (1 ng/ml) for 12 h in the presence
or absence of indomethacin (1 M) or NS-
398 (5 M). Levels of PGE2 and 6-keto PGF1
in supernatants were detected by ELISA. Data
are expressed as the mean  sem for three
embryo lines. *, ** Indicate statistical signifi-
cance at P  0.05 and P  0.01, respectively.
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stable breakdown products, nitrite, and nitrate. There-
fore, in the present study we assessed the effect of
mPGES-1 deletion on the levels of nitrite in mPGES-1
WT and null MEFs. Results showed that low levels of
nitrite were detectable in unstimulated mPGES-1 WT
and null MEFs. However, stimulation with IL-1 re-
sulted in a significant increase in the levels of nitrite in
both mPGES-1 WT and null MEFs (Fig. 7). Nitrite levels
in the mPGES-1 null MEFs were significantly higher
compared to their WT counterparts, concordant with
iNOS expression data.
Similarly, as observed with iNOS expression data, a
substantial elevation in the levels of nitrite was ob-
served in IL-1 stimulated mPGES-1 WT MEFs
treated with indomethacin and NS-398 (Fig. 7).
However, indomethacin and NS-398 treatment
showed no significant up-regulation in the levels of
nitrite in IL-1 stimulated mPGES-1 null MEFs, sug-
gesting that there was little further contribution of
COX inhibition when mPGES-1 was deleted. In addi-
tion, treatment with exogenous PGE2 reduced the
levels of nitrite in mPGES-1 null MEFs only, bringing
the levels similar to mPGES-1 WT MEFs. These
results further indicate that mPGES-1 and COX-2-
derived PGE2 negatively regulate iNOS expression
and nitrite synthesis during inflammation.
DISCUSSION
This study using MEFs isolated from mPGES-1-deficient
mice clearly draws out three major conclusions. First,
genetic deletion of mPGES-1 results in a dramatic
decrease in PGE2 production in mPGES-1 Het and null
MEFs in a gene dose-dependant manner, under basal
and IL-1 stimulation, suggesting that mPGES-1 is
critical for PGE2 production in these cells. Second, this
study demonstrates a shunting phenomenon within the
AA metabolic pathway as a result of mPGES-1 gene
deletion with higher levels of 6-keto PGF1 in mPGES-1
Het and null MEFs compared to their WT counterparts,
also in a gene dose-dependent manner. Third, we show
that mPGES-1 gene deletion and resultant decrease in
PGE2 production results in a differential expression
Figure 5. Levels of PGE2 and 6-keto PGF1 production in
COX-2 WT, Het, and null MEFs. A) Genotyping of COX-2
WT, Het, and null mice. Protein levels of COX-2 in COX-2
WT, Het, and null MEFs were determined by Western blot-
ting. Ovine standard COX-2 protein was used as a positive
control. B) COX-2 WT, Het, and null MEFs were incubated
with IL-1 (1 ng/ml) for 12 h. Levels of PGE2, 6-keto PGF1
in supernatants were detected by ELISA. Data are expressed
as the mean  sem for three embryo lines. *, ** Indicate
statistical significance at P  0.05 and P  0.01, respectively.
Figure 6. Levels of iNOS and eNOS expression in mPGES-1 WT and null MEFs: Effect of NSAIDs and PGE2. mPGES-1 WT and
null MEFs were incubated with or without IL-1 (1 ng/ml) for 12 h in the presence or absence of indomethacin (1 M), NS-398
(5 M), and PGE2 (1 M) and protein expressions of iNOS, eNOS, and -actin were determined by Western blotting.
Representative blots from three embryo lines are shown.
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profile of iNOS and nitrite levels in mPGES-1 WT MEFs
compared with null MEFs. Furthermore, using nonse-
lective and selective COX-2 inhibitors and treatment
with exogenous PGE2, we show that COX-2- and
mPGES-1-derived PGE2 acts as a negative regulator of
iNOS expression and nitrite synthesis during an inflam-
matory insult in mPGES-1 MEFs.
mPGES-1 is critical for PGE2 production
We and others have previously shown that increase in
PGE2 production is associated with up-regulation of
mPGES-1 along with COX-2 in variety of cells and
tissues including synovial fibroblasts (14, 15, 21, 24)
and synovial tissue (13, 25) isolated from patients with
0
10
20
30
40
µ
M
 N
it
ri
te
 / 
m
l
WT null
- +- +IL-1?
indomethacin NS-398
WT null WT null
- +- +
WT null WT null
- +- +
WT null WT null
- +- +
WT null
PGE2
**
* **
**
**
**
Figure 7. Differential levels of nitrite in mPGES-1 WT and null MEFs: Effect of NSAIDs and PGE2. mPGES-1 WT and null MEFs
were incubated with or without IL-1 (1 ng/ml) for 12 h in the presence or absence of indomethacin (1 M), NS-398 (5 M),
and PGE2 (1 M). Levels of nitrite in supernatants were detected by ELISA. Data are expressed as the mean  sem for three
embryo lines. *, ** Indicate statistical significance at P  0.05 and P  0.01, respectively.
Schematic diagram. Prostanoid diversion profile in mPGES-1 deletion versus COX-2 deletion/inhibition: regulation of iNOS
and NO.
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RA and OA, articular cartilage and chondrocytes iso-
lated from patients with OA (20, 24). The present study
for the first time demonstrates the role of mPGES-1 in
fibroblast biology using mPGES-1 null MEFs. Results
show that coordinated induction of COX-2 and
mPGES-1 is concomitantly accompanied by the in-
crease in PGE2 levels in MEFs. Using cytokine-stimu-
lated and unstimulated mPGES-1 Het and null MEFs,
we show that PGE2 levels significantly drop as a result of
mPGES-1 gene deletion in a gene dose-dependent
fashion, further emphasizing the fact that mPGES-1
along with COX-2 is critical for PGE2 synthesis under
basal as well as inflammatory conditions. This is despite
the fact that COX-1, cPGES and mPGES-2 are ex-
pressed in these cells. These results support the studies
by other groups that have also shown that mPGES-1 is
essential for PGE2 production and deletion of mPGES-1
gene results in a dramatic decline in PGE2 levels in
peritoneal macrophages (16, 17, 26–28) and microglia
(29).
Shunting of endogenous prostanoid biosynthesis with
mPGES-1 gene deletion
Using mPGES-1 WT, Het, and null MEFs in the present
study, we show that genetic deletion of mPGES-1 results
in the diversion of the prostanoid production profile
from predominant PGE2 to 6-keto PGF1 under basal as
well as proinflammatory cytokine-stimulated conditions
in a gene dose-dependent manner without any signifi-
cant changes in the levels of other prostanoids includ-
ing PGD2 and TXB2. We also investigated if PGIS was
up-regulated in mPGES-1 null MEFs resulting in the
redirection of PGE2 to 6-keto PGF1 following mPGES-1
gene deletion. However, no significant changes in the
mRNA and protein levels of PGIS and other PG syn-
thetic enzymes (mPGES-2, cPGES, PGIS, h-PGDS, TXS,
and COX-1) were observed with mPGES-1 gene dele-
tion under basal or IL-1 stimulated conditions. These
results indicate that in the absence of induced
mPGES-1, elevation of COX-2 after inflammatory insult
and the resultant increase in the availability of PGH2 as
the common substrate for the generation of other
prostanoids account for increased levels of 6-keto
PGF1 observed with mPGES-1 deletion in mPGES-1
Het and null MEFs.
A previous study using mouse peritoneal macro-
phages derived from mPGES-1 null mice (DBA/1lacJ
genetic background) also supports the presence of
shunting in the prostanoid biosynthesis (26). That
study showed that PGE2 was the predominant prosta-
noid produced in the lipopolysaccharide (LPS)-stim-
ulated mPGES-1 WT mouse peritoneal macrophages.
In contrast, incubation of mPGES-1 null mouse peri-
toneal macrophages with LPS resulted in a significant
decrease in the levels of PGE2 but significant increase
in the levels of other prostanoids in the order of
TXB2  6-keto PGF1  PGF2  PGD2  PGE2. This
study also showed that the mPGES-1 gene deletion
did not result in any change in the expression levels
of PGIS and TXS.
Another study using mouse peritoneal macrophages
isolated from mPGES-1 null mice (129P2C57Bl/6
genetic background) also showed that PGE2 was the
predominant prostanoid produced in the LPS-stimu-
lated mPGES-1 WT mouse peritoneal macrophages
(27). However, mPGES-1 gene deletion resulted in a
significant increase in the levels of PGF2, but only
numerical increase in the levels of TXB2 and no change
in the levels of 6-keto PGF1 in mPGES-1 Het and null
mouse peritoneal macrophages compared to their WT
counterparts. These two studies (26, 27) in comparison
with the present study emphasize the cell specificity of
prostanoid rediversion.
mPGES-1- and COX-2-derived PGE2 regulates iNOS
expression and nitrite biosynthesis in mPGES-1 MEFs
iNOS is not normally expressed under basal conditions
in tissues and cells but is highly inducible in response to
inflammatory cytokines and bacterial endotoxins (30).
iNOS catalyzes the conversion of L-arginine to L-
citrulline and NO (31). NO is a highly unstable free
radical gas that is rapidly converted into stable break-
down products called nitrite and nitrate. NO is involved
in the physiological regulation of the vasculature (va-
sodilation), neurotransmission, host defense mecha-
nisms, and various pathophysiological processes (32–
34).
In this study for the first time, we provide evidence
that mPGES-1 deletion and resultant decrease in PGE2
lead to an up-regulation of iNOS expression and nitrite
biosynthesis under proinflammatory cytokine-stimu-
lated conditions. Data using NSAID (indomethacin and
NS-398) and PGE2-treated MEFs and in combination
with or without mPGES-1 gene deletion further dem-
onstrate that mPGES-1- and COX-2-derived PGE2 neg-
atively regulates iNOS expression and nitrite biosynthe-
sis. Because high levels of 6-keto PGF1 correlated with
the high levels of nitrite observed in IL-1-stimulated
mPGES-1 null MEFs compared with WT MEFs, we
investigated whether 6-keto PGF1 had any contribu-
tion toward the regulation of nitrite synthesis in these
cells. Blocking high levels of 6-keto PGF1 in mPGES-1
null MEFs by indomethacin and NS-398 treatments had
no effect on the high levels of nitrite which remained
unaltered. These results suggest that PGI2 and PGE2
may not be equivalently involved in the regulation of
nitrite synthesis.
Previous studies have also suggested that COX-2-
derived prostanoids, mainly PGE2, may be involved in
the crosstalk with iNOS and NO during inflammatory
conditions, predominantly in macrophages (23, 35–7).
It has been shown that treatment with PGE2 decreases
the levels of iNOS expression and nitrite biosynthesis in
LPS-stimulated J774 macrophages (37). On the other
hand, endogenous NO also has the ability to suppress
the production of PGE2 in LPS-treated RAW 264.7
murine macrophages (35).
E1713PGs AND NITRITE IN mPGES-1 DEFICIENCY
Pharmacological significance of prostanoid diversion
associated with mPGES-1 deletion
PGE2 is a key proinflammatory mediator derived from
COX-2 and mPGES-1, which has been shown to be
elevated in various chronic inflammatory disorders,
including RA, OA, atherosclerosis, Alzheimer’s disease,
and various forms of cancers (14, 15, 20, 21, 24,
38–40). COX-2 selective inhibitors exert their antiin-
flammatory pharmacological effects by inhibiting the
excessive production of PGE2 at the site of inflamma-
tion. However, recent clinical studies have suggested
serious cardiovascular side effects associated with the
use of COX-2 inhibitors (4–6). One of the hypotheses
put forward to explain the cardiovascular effects of
COX-2 inhibition is the loss of antithrombotic PGI2
derived from endothelial COX-2, which plays a key role
in the regulation of thrombogenesis (41).
In the present study we demonstrate that genetic
deletion of mPGES-1 results in transition in the pro-
duction pattern from PGE2 to 6-keto PGF1, whereas
pharmacological inhibition and genetic deletion of
COX-2 results in dramatic decrease in the levels of not
only PGE2 but also 6-keto PGF1. In addition, our
results demonstrate that mPGES-1 gene deletion causes
elevation of nitrite levels. 6-keto PGF1 and nitrite are
stable metabolites of PGI2 and NO, which are involved
in vasodilatation and maintenance of vascular ho-
meostasis (32, 42, 43). Clinical studies have also indi-
cated the beneficial effects of PGI2 and NO for the
management of circulatory disorders (44). In view of
the above facts, mPGES-1 pharmacological inhibition
may not be associated with cardiovascular side effects
seen with inhibition of COX-2. The efficacy of such a
therapeutic strategy remains unclear since increased
levels of PGI2 and NO could also exert proinflamma-
tory effects as observed in the studies using PGI2
receptor and iNOS deficient mice (45–47). In light of
our present results, however, inhibition of mPGES-1
continues to be an attractive therapeutic target for
PGE2 inhibition in inflammatory conditions.
Authors would like to thank Dr. Seetha Monrad and Dr.
Annaleise Sampey (University of Michigan) for their helpful
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SPECIFIC AIMS
Microsomal prostaglandin E synthase-1 (mPGES)-1 is the
inducible enzyme that acts downstream of cyclooxygenase
(COX) and catalyzes the conversion of prostaglandin
(PG) H2 to PGE2. Specific inhibitors of mPGES-1 are not
yet available, however, mice with genetic deletion of
mPGES-1 have been generated that have given insight
into the specific role of mPGES-1 in eicosanoid biosynthe-
sis in vivo and in peritoneal macrophages. We hypothe-
sized that creating mouse embryo fibroblast (MEF) cell
lines would facilitate investigation of the role of mPGES-1
in fibroblast biology. We generated MEF from heterozy-
gous matings to create mPGES-1 null, mPGES-1 Het, and
mPGES-1 wild-type (WT) lines.
Aims of this study were to:
1. Evaluate the effect of genetic deletion of mPGES-1
on the expression of major prostanoid biosynthetic
enzymes including COX-2, COX-1, mPGES-2, cytosolic
PGES (cPGES), PGIS, hematopoietic-PGDS (h-PGDS),
thromboxane synthase (TXS).
2. Evaluate the effect of genetic deletion of mPGES-1
on the production pattern of major prostanoids includ-
ing PGE2, 6-keto PGF1 (stable metabolic product of
PGI2), PGD2, and TXB2 (stable metabolic product of
TXA2) in order to evaluate the shunting possibility
within the arachidonic acid (AA) metabolic pathway.
3. Evaluate and compare the consequences of ge-
netic deletion and pharmacological inhibition of
COX-2 vs. genetic deletion of mPGES-1 on prostanoid
biosynthesis in MEFs.
4. Evaluate the effect of genetic deletion of mPGES-1
and subsequent effect of prostanoid biosynthesis on the
regulation of other inflammatory enzyme outside the
arachidonic acid (AA) metabolic pathway, inducible
nitric oxide synthase (NOS) (iNOS) and endothelial
NOS (eNOS), and production profile of NOS stable
metabolic product, nitrite.
PRINCIPAL FINDINGS
1. mPGES-1 is critical for PGE2 production
The present study for the first time demonstrates the
role of mPGES-1 in fibroblast biology using mPGES-1
null MEFs. Results show that coordinated induction of
COX-2 and mPGES-1 is concomitantly accompanied by
the increase in PGE2 levels in MEFs. Using interleukin
(IL)-1 stimulated and unstimulated mPGES-1 Het and
null MEFs, we show that PGE2 levels significantly drop
as a result of mPGES-1 gene deletion in a gene-dose
dependent fashion, further emphasizing the fact that
mPGES-1 is essential for PGE2 synthesis. This is despite
the fact that COX-1, cPGES, and mPGES-2 are ex-
pressed in these cells under basal and stimulated con-
ditions and COX-2 is dramatically up-regulated by
IL-1. These results support the studies by other groups
that have also shown that mPGES-1 is critical for PGE2
production and deletion of mPGES-1 gene results in a
dramatic decline in PGE2 levels in peritoneal macro-
phages and microglia.
2. Shunting of endogenous prostanoid biosynthesis
with mPGES-1 gene deletion
Using mPGES-1 WT, Het, and null MEFs in the present
study, we show that genetic deletion of mPGES-1 results
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in the diversion of the prostanoid production profile
from predominant PGE2 to 6-keto PGF1 under basal as
well as proinflammatory cytokine-stimulated conditions
in a gene dose-dependent manner without any signifi-
cant changes in the levels of other prostanoids, includ-
ing PGD2 and TXB2. Furthermore, there is no evidence
of shunting to PGD2 and TXB2 despite presence of
PGDS, TXS, and other terminal biosynthetic enzymes
in these cells. We also investigated whether PGIS was
up-regulated in mPGES-1 null MEFs resulting in the
redirection of PGE2 to 6-keto PGF1 following mPGES-1
gene deletion. However, no significant changes in the
mRNA and protein levels of PGIS and other PG syn-
thetic enzymes (mPGES-2, cPGES, PGIS, H-PGDS, TXS,
and COX-1) were observed with mPGES-1 gene dele-
tion under basal or IL-1 stimulated conditions. These
results indicate that in the absence of induced
mPGES-1, elevation of COX-2 after inflammatory insult
and the resultant increase in the availability of PGH2 as
the common substrate for the generation of other
prostanoids could account for increased levels of 6-keto
PGF1 observed with mPGES-1 deletion in mPGES-1
Het and null MEFs.
3. Absence of diversion of prostanoid biosynthesis
from PGE2 to 6-keto PGF1 with COX-2
pharmacological inhibition and genetic deletion
In the present study we demonstrate that, unlike
mPGES-1 deletion, COX-2 pharmacological inhibition
and genetic deletion do not result in transition in the
production pattern from PGE2 to 6-keto-PGF1. Using
genetically deleted COX-2 MEFs and pharmacological
inhibition with nonsteroidal antiinflammatory drugs
(NSAID) such as selective COX-2 inhibitor (NS-398)
and nonselective COX inhibitor (Indomethacin), we
show that deletion/inhibition of COX-2 results in dra-
matic decrease in the levels of not only PGE2 but also
6-keto PGF1, thus showing clear differences between
COX-2 vs. mPGES-1 inhibition on prostanoid synthesis
profile in MEFs.
4. mPGES-1 and COX-2-derived PGE2 regulates iNOS
expression and nitrite biosynthesis in mPGES-1 MEFs
In this study for the first time, we provide evidence that
mPGES-1 deletion leads to up-regulation of iNOS ex-
pression and nitrite biosynthesis under proinflamma-
tory cytokine-stimulated conditions. We observed that
the levels of iNOS expression and nitrite biosynthesis in
IL-1 stimulated mPGES-1 null MEFs were significantly
higher in comparison to low levels observed in
mPGES-1 WT MEFs, which suggested that PGE2 may be
involved in the regulation of iNOS and nitrite in these
MEFs. To prove the involvement of PGE2 toward the
regulation of iNOS and nitrite, we used NSAID (indo-
methacin and NS-398) treatment and exogenous PGE2
administration approaches in MEFs. Treatment with
NSAIDs and resultant decrease in PGE2 levels up-
regulated the levels of iNOS expression and nitrite
synthesis in mPGES-1 WT MEFs, similar to the levels
observed in mPGES-1 null MEFs. Similarly, exogenous
administration of PGE2 reversed the enhanced iNOS
expression and nitrite biosynthesis in mPGES-1 null
MEFs, similar to the levels of mPGES-1 WT MEFs. Thus
these results prove the fact that PGE2 derived from
mPGES-1 and COX-2 negatively regulates iNOS expres-
sion and nitrite biosynthesis in MEFs.
Schematic diagram. Prostanoid diversion profile in mPGES-1 deletion versus COX-2 deletion/inhibition: Regulation of iNOS
and NO.
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CONCLUSION AND SIGNIFICANCE
PGE2 is a key proinflammatory mediator derived from
COX-2 and mPGES-1, which has been shown to be
elevated in various chronic inflammatory disorders,
including reumatoid arthritis (RA), osteoarthritis
(OA), atherosclerosis, Alzheimer’s disease, and various
forms of cancer. COX-2 selective inhibitors exert their
antiinflammatory pharmacological effects by inhibiting
the excessive production of PGE2 at the site of inflam-
mation. However, recent clinical studies have suggested
serious cardiovascular side effects associated with the
use of COX-2 inhibitors. One of the hypotheses put
forward to explain the cardiovascular effects of COX-2
inhibition is the loss of antithrombotic PGI2 derived
from endothelial COX-2, which plays a key role in the
regulation of thrombogenesis.
In the present study we demonstrate that genetic
deletion of mPGES-1 results in transition in the pro-
duction pattern from PGE2 to 6-keto-PGF1, whereas
pharmacological inhibition and genetic deletion of
COX-2 results in dramatic decrease in the levels of not
only PGE2 but also 6-keto-PGF1. In addition, our
results demonstrate that mPGES-1 gene deletion and
subsequent decrease in the levels of PGE2 causes eleva-
tion of nitrite levels. 6-keto-PGF1 and nitrite are stable
metabolites of PGI2 and NO, which are involved in
vasodilatation and maintenance of vascular homeosta-
sis. Clinical studies have also indicated the beneficial
effects of PGI2 and NO for the management of circu-
latory disorders. In view of the above facts, mPGES-1
pharmacological inhibition may escape the cardiovas-
cular side effects seen with inhibition of COX-2. The
efficacy of such a therapeutic strategy remains unclear
since increased levels of PGI2 and NO could also exert
proinflammatory effects as observed in the studies
using PGI2 receptor and iNOS deficient mice. In light
of our present results, however, inhibition of mPGES-1
continues to be an attractive therapeutic target for
PGE2 inhibition in inflammatory conditions.
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